{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:46:54Z","timestamp":1757623614129,"version":"3.44.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100014351","name":"CinnaGen","doi-asserted-by":"publisher","award":["701\/371"],"award-info":[{"award-number":["701\/371"]}],"id":[{"id":"10.13039\/501100014351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16351-4","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T15:48:36Z","timestamp":1755618516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of a biosimilar laronidase versus the reference laronidase in patients with mucopolysaccharidosis type I"],"prefix":"10.1038","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06406153","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4792-0096","authenticated-orcid":false,"given":"Ali","family":"Rabbani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Alaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samaneh Norouzi","family":"Asl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aria","family":"Setoodeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Shakiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadab","family":"Salehpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Eshraghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Salehpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araz","family":"Sabzvari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Kafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Jarollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"16351_CR1","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3390\/cells9081838","volume":"9","author":"CS Hampe","year":"2020","unstructured":"Hampe, C. S. et al. Mucopolysaccharidosis type I: a review of the natural history and molecular pathology. Cells 9, 1838 (2020).","journal-title":"Cells"},{"key":"16351_CR2","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.4103\/ijo.IJO_425_22","volume":"70","author":"R Nagpal","year":"2022","unstructured":"Nagpal, R. et al. Mucopolysaccharidosis: a broad review. Indian J. Ophthalmol. 70, 2249\u20132261 (2022).","journal-title":"Indian J. Ophthalmol."},{"key":"16351_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ymgme.2020.02.006","volume":"130","author":"E Kakkis","year":"2020","unstructured":"Kakkis, E. & Marsden, D. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses. Mol. Genet. Metab. 130, 7\u201315 (2020).","journal-title":"Mol. Genet. Metab."},{"key":"16351_CR4","doi-asserted-by":"publisher","first-page":"CD009354","DOI":"10.1002\/14651858.CD009354.pub5","volume":"6","author":"E Jameson","year":"2019","unstructured":"Jameson, E., Jones, S. & Remmington, T. Enzyme replacement therapy with laronidase (Aldurazyme((R))) for treating mucopolysaccharidosis type I. Cochrane Database Syst. Rev. 6, CD009354. https:\/\/doi.org\/10.1002\/14651858.CD009354.pub5 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"16351_CR5","doi-asserted-by":"publisher","unstructured":"Coutinho, M. F., Lacerda, L. & Alves, S. Glycosaminoglycan storage disorders: a review. Biochem. Res. Int. 2012, 471325. https:\/\/doi.org\/10.1155\/2012\/471325 (2012).","DOI":"10.1155\/2012\/471325"},{"key":"16351_CR6","doi-asserted-by":"publisher","unstructured":"Muenzer, J., Wraith, J. E. & Clarke, L. A. International Consensus Panel on, M. & Treatment of Mucopolysaccharidosis, I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 123, 19\u201329. https:\/\/doi.org\/10.1542\/peds.2008-0416   (2009).","DOI":"10.1542\/peds.2008-0416"},{"key":"16351_CR7","doi-asserted-by":"publisher","unstructured":"Hampe, C. S. et al. Mucopolysaccharidosis type I: a review of the natural history and molecular pathology. Cells 9, 856. https:\/\/doi.org\/10.3390\/cells9081838 (2020).","DOI":"10.3390\/cells9081838"},{"key":"#cr-split#-16351_CR8.1","unstructured":"LA, C. Mucopolysaccharidosis Type I. Oct 31 [Updated 2024 Apr 11]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle"},{"key":"#cr-split#-16351_CR8.2","unstructured":"1993-2025. (2002). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1162\/."},{"key":"16351_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s10038-019-0662-9","volume":"64","author":"HH Chen","year":"2019","unstructured":"Chen, H. H. et al. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J. Hum. Genet. 64, 1153\u20131171 (2019).","journal-title":"J. Hum. Genet."},{"key":"16351_CR10","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/biom11121775","volume":"11","author":"C Fern\u00e1ndez-Pereira","year":"2021","unstructured":"Fern\u00e1ndez-Pereira, C. et al. Therapeutic approaches in lysosomal storage diseases. Biomolecules 11, 1775 (2021).","journal-title":"Biomolecules"},{"key":"16351_CR11","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. CHMP\/437\/04 Rev 1.  (2014). https:\/\/www.sergas.es\/Asistencia-sanitaria\/Documents\/1000\/guideline%20on%20similar%20biological%20medicinal%20products%20EMA.pdf."},{"key":"16351_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-8-147","volume":"8","author":"SP Lin","year":"2013","unstructured":"Lin, S. P. et al. A pilot newborn screening program for mucopolysaccharidosis type I in Taiwan. Orphanet J. Rare Dis. 8, 1\u20138 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"16351_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown, E. G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 20, 109\u2013117. https:\/\/doi.org\/10.2165\/00002018-199920020-00002 (1999).","journal-title":"Drug Saf."},{"key":"16351_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112, 90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009 (2021).","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"16351_CR15","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Maintenance of the ICH guideline on clinical safety data management: data elements for transmission of individual case safety reports E2B(R2). 2001..https:\/\/admin.ich.org\/sites\/default\/files\/inline-files\/E2B_R2_Guideline.pdf."},{"key":"16351_CR16","unstructured":"Uppsala Monitoring Centre, The use of the WHO-UMC system for standardised case causality assessment. 2018., https:\/\/who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf."},{"key":"16351_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith, J. E. et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of Recombinant human \u03b1-L-iduronidase (laronidase). J. Pediatr. 144, 581\u2013588 (2004).","journal-title":"J. Pediatr."},{"key":"16351_CR18","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith, J. E. et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of Recombinant human \u03b1-L-iduronidase (laronidase). Pediatrics 120, e37\u2013e46 (2007).","journal-title":"Pediatrics"},{"key":"16351_CR19","unstructured":"Laronidase : Drug information. https:\/\/www.uptodate.com\/contents\/laronidase-drug-information?search=laronidase&source=panel_search_result&selectedTitle=1%7E3&usage_type=panel&kp_tab=drug_general&display_rank=1#references."},{"key":"16351_CR20","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/ajmg.a.31831","volume":"143","author":"G Wegrzyn","year":"2007","unstructured":"Wegrzyn, G. et al. Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy. Am. J. Med. Genet.: A. 143, 1925 (2007).","journal-title":"Am. J. Med. Genet.: A"},{"key":"16351_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","volume":"96","author":"R Giugliani","year":"2009","unstructured":"Giugliani, R. et al. A dose-optimization trial of laronidase (Aldurazyme\u00ae) in patients with mucopolysaccharidosis I. Mol. Genet. Metab. 96, 13\u201319 (2009).","journal-title":"Mol. Genet. Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16351-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T07:22:18Z","timestamp":1757402538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16351-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16351"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16351-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hamidreza Kafi is the head of the medical department of Orchid Pharmed Company which is in collaboration with CinnaGen company with respect to conducting clinical trials. Araz Sabzvari is a member of CinnaGen medical biotechnology research center. This research center collaborates with universities and researchers all over the world with regards to research and development of medications and health issues. Other authors have no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and its later amendments, and with Good Clinical Practice guidelines. Approval was granted by the ethics committee of Tehran University of Medical Sciences (IR.TUMS.TIPS.REC.1401.001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all legal guardians of the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"30427"}}